ACURX PHARMACEUTICALS INC (ACXP)

Company Profile

Acurx Pharmaceuticals, Inc. operates as a clinical stage biopharmaceutical company, which engages in developing new antibiotics for infections caused by bacteria listed as priority pathogens. The company is headquartered in Staten Island, New York and currently employs 4 full-time employees. The company went IPO on 2021-06-25. The firm is focused on developing a new class of antibiotics for infections caused by bacteria listed as priority pathogens by the World Health Organization (WHO), the United States Centers for Disease Control and Prevention (CDC) and the United States Food and Drug Administration (FDA). The firm develops antibiotic candidates that block the deoxyribonucleic acid (DNA) polymerase IIIC enzyme (Pol IIIC). Pol IIIC is the primary catalyst for DNA replication in Gram-positive bacterial cells. The Company’s research and development pipeline includes clinical-stage and early-stage antibiotic candidates that target Gram-positive bacteria for oral and/or parenteral treatment of infections caused by Clostridium difficile; Enterococcus, including vancomycin-resistant strain; Staphylococcus, including methicillin-resistant strains, and Streptococcus, including antibiotic resistant strains).

Company Info

ACURX PHARMACEUTICALS INC

259 Liberty Avenue

Staten Island NEW YORK

P: 19175331469

CEO: David P. Luci

Employees: 4

Website: https://www.acurxpharma.com/